AstraZeneca's Fasenra Falls Short In Smoker's Lung Trial

Benzinga

2025/09/18

AstraZeneca Plc AZN released on Wednesday topline data from RESOLUTE Phase 3 trial of Fasenra (benralizumab). AZN is showing upward bias. Get the complete picture here. Fasenra, despite showing ...

网页链接

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2568415506"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2568415506\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2568415506?lang=zh_TW&edition=fundamental","thumbnail":"https://cdn.benzinga.com/files/images/story/2025/09/17/Konskie--Poland---January-03--2024-Astra.jpeg?optimize=medium&dpr=2&auto=webp&width=260","is_english":true,"pubTime":"2025-09-18 01:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2568415506","market":"us","top_or_hot":-1,"title":"AstraZeneca's Fasenra Falls Short In Smoker's Lung Trial","media":"Benzinga","content":"<div>\n<p>AstraZeneca Plc AZN released on Wednesday topline data from RESOLUTE Phase 3 trial of Fasenra (benralizumab).\nAZN is showing upward bias. Get the complete picture here.\nFasenra, despite showing ...</p>\n\n<a href=\"https://www.benzinga.com/markets/large-cap/25/09/47721938/astrazenecas-fasenra-falls-short-in-smokers-lung-trial\">网页链接</a>\n\n</div>\n","source":"benzinga_hot_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>AstraZeneca's Fasenra Falls Short In Smoker's Lung Trial</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAstraZeneca's Fasenra Falls Short In Smoker's Lung Trial\n</h2>\n<h4 class=\"meta\">\n<p class=\"head\">\n<strong class=\"h-name small\">Benzinga</strong><span class=\"h-time small\">2025-09-18 01:20</span>\n</p>\n</h4>\n</header>\n<article>\n<div>\n<p>AstraZeneca Plc AZN released on Wednesday topline data from RESOLUTE Phase 3 trial of Fasenra (benralizumab).\nAZN is showing upward bias. Get the complete picture here.\nFasenra, despite showing ...</p>\n\n<a href=\"https://www.benzinga.com/markets/large-cap/25/09/47721938/astrazenecas-fasenra-falls-short-in-smokers-lung-trial\">网页链接</a>\n\n</div>\n\n<div class=\"bt-text\">\n\n\n<p> 來源：<a href=\"https://www.benzinga.com/markets/large-cap/25/09/47721938/astrazenecas-fasenra-falls-short-in-smokers-lung-trial\">Benzinga</a></p>\n<p>為提升您的閱讀體驗，我們對本頁面進行了排版優化</p>\n\n\n</div>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4077","symbol_name":"互動媒體與服務","start_time":0,"source_url":"https://www.benzinga.com/markets/large-cap/25/09/47721938/astrazenecas-fasenra-falls-short-in-smokers-lung-trial","article_id":"2568415506","we_media_id":null,"thumbnails":["https://cdn.benzinga.com/files/images/story/2025/09/17/Konskie--Poland---January-03--2024-Astra.jpeg?optimize=medium&dpr=2&auto=webp&width=260"],"rights":{"source":"benzinga_hot_news","url":"https://www.benzinga.com/markets/large-cap/25/09/47721938/astrazenecas-fasenra-falls-short-in-smokers-lung-trial","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2568415506","pubTimestamp":1758129600,"columns":[],"sourceInfo":{"source_id":"benzinga_hot_news","name":"Benzinga"},"weMediaInfo":null,"summary":"AstraZeneca's Fasenra misses the primary COPD endpoint while Saphnelo's lupus trial shows significant improvements and consistent safety profiles.","collect":0,"end_time":0,"defaultTopTitle":"benzinga.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4077":"互动媒体与服务","SEA":"U.S. Global Sea to Sky Cargo ETF","SLE":"Super League Gaming Inc."},"translate_title":"阿斯利康的Fasenra在吸烟者肺部试验中表现不佳","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SLE":1,"SEA":1},"content_text":"AstraZeneca Plc AZN released on Wednesday topline data from RESOLUTE Phase 3 trial of Fasenra (benralizumab).\nAZN is showing upward bias. Get the complete picture here.\nFasenra, despite showing numerical improvement, did not achieve statistical significance in the primary endpoint in patients with chronic obstructive pulmonary disease (COPD), also known as smoker’s lung disease.\nThe safety and tolerability profile for Fasenra in the trial was consistent with the known profile of the medicine.\nThe company will analyse the full data set from RESOLUTE.\nFasenra is currently approved as an add-on maintenance treatment for severe eosinophilic asthma (SEA) in more than 80 countries, including the US, Japan, the EU, and China.\nIt is also approved for SEA in children and adolescents aged six and above in the U.S. and Japan.\nFasenra has also been approved in more than 60 countries for the adult treatment of eosinophilic granulomatosis with polyangiitis, and it is under regulatory review for the treatment of hypereosinophilic syndrome.\nAstraZeneca also shared high-level results from a pre-specified interim analysis of the Phase 3 TULIP-SC trial in patients with systemic lupus erythematosus (SLE).\nThe trial showed the subcutaneous (SC) administration of AstraZeneca's Saphnelo (anifrolumab) demonstrated a statistically significant and clinically meaningful reduction in disease activity compared to placebo.\nAlso Read: Regeneron, Sanofi Stock Falls After Uneven Smoker’s Lung Drug Data\nThe safety profile observed in the interim analysis was consistent with the known clinical profile of Saphnelo administered as an intravenous (IV) infusion.\nThe reduction in disease activity in TULIP-SC was measured using the British Isles Lupus Assessment Group-based Composite Lupus Assessment (BICLA) at week 52.\nThe BICLA requires improvement in all organs with disease activity at baseline, with no new flares.\nThe TULIP-SC interim results are under regulatory review.\nSaphnelo IV infusion is approved for moderate to severe SLE in more than 70 countries.\nAZN Price Action: AZN stock is up 0.11% at $77.64 at the publication on Wednesday.\nRead Next:\nPhoto by Piotr Swat via Shutterstock","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}